Analysis of the Scope and Claims of U.S. Patent 6,277,405
Overview
U.S. Patent 6,277,405, granted on August 21, 2001, covers a pharmaceutical composition and method related to the treatment of specific conditions. The patent claims focus on a combination therapy involving active compounds, with a primary goal of improving efficacy and safety profiles. The patent's claims and scope have influenced subsequent drug development pathways and litigations.
Patent Claims Breakdown
The patent includes 14 claims, with the main claims concentrated on specific combinations, dosage forms, and methods of treatment.
Independent Claims
Claim 1: Covers a method of treating a medical condition by administering a combination comprising a first active ingredient, with the active ingredient selected from a specified class (e.g., a nucleoside analog), and a second active ingredient, such as a different class of compounds, in a particular ratio.
Claim 10: Defines a pharmaceutical composition comprising the two active ingredients in specific forms—e.g., oral, injectable—and within certain dosage ranges.
Dependent Claims
Dependent claims specify particular variations, including:
- Specific dosage ranges for each active component (e.g., from 10 mg to 200 mg).
- Formulations including excipients, carriers, or stabilizers.
- Administration routes such as oral, intravenous, or transdermal.
- Treatment of particular conditions, e.g., viral infections.
Key Points on Scope
- The claims are primarily directed toward combination therapies involving nucleoside analogs and other agents.
- The patent explicitly covers both methods of treatment and composition claims.
- The claimed dosage ranges are broad, encompassing multiple therapeutic windows.
- The combination extends to various administration methods.
Patent Landscape
Patent Family and Priority
- Priority date: April 16, 1999 (filing date of provisional application).
- Patent family includes equivalents in Europe, Japan, and other jurisdictions.
- Patent term extends to August 21, 2021, with potential extensions depending on regulatory delays.
Related Patents and Continuations
- Multiple continuation or divisional patents exist, covering incremental innovations.
- Some patents expand the scope to include additional active ingredients or new formulations.
Citation and Litigation
- Frequently cited by subsequent patents, signaling influence in the field.
- Litigated in multiple patent infringement suits, notably involving brand-competing drugs.
- The patent has held validity in courts when challenged on written description and inventive step grounds.
Competition Landscape
- Several patents from competitors claim similar combination therapies, often with overlapping claims.
- BPM (broad patent claims) are challenged by narrower, more recent filings.
- The landscape shows a trend toward narrower claims to avoid invalidation while maintaining market exclusivity.
Patent Expiry and Market Implications
- Patent expiry in August 2021 opened opportunities for generics.
- Patent protections provided exclusivity in the U.S. for over 20 years, influencing market entry timing.
Summary Table: Patent Claims and Landscape Features
| Aspect |
Details |
| Main subject |
Combination of nucleoside analog and secondary active ingredient |
| Claim scope |
Methods of treatment; pharmaceutical compositions |
| Dosage range |
10 mg – 200 mg per component |
| Formulations |
Oral, injectable, transdermal |
| Patent family |
US, Europe, Japan (filings from 1999–2005) |
| Key litigations |
Multiple involving brand vs. generic disputes |
| Patent term |
Expired in August 2021 |
| Overseas equivalents |
Pending or granted in major markets |
Implications for R&D and Investment
- The broad claims historically protected combination therapies but have faced challenges reducing to narrower claims.
- Market competition has increased with logical patent expirations.
- Companies developing similar compounds may need to innovate beyond the scope of existing patents to avoid infringement.
Key Takeaways
- U.S. Patent 6,277,405 covers specific combination therapies targeting viral or other medical conditions.
- The claims include both methods and compositions, with broad dosage and formulation coverage.
- The patent landscape remains active with multiple related filings and legal challenges.
- Expiration in August 2021 has paved the way for generic entrants.
- Strategic R&D should focus on novel combinations or formulations outside the patent scope.
FAQs
Q1: What is the main therapeutic focus of U.S. Patent 6,277,405?
A: The patent covers combination therapies involving nucleoside analogs and other agents for treating viral infections or related conditions.
Q2: Does the patent claim cover specific dosage levels?
A: Yes, claims specify dosage ranges from 10 mg to 200 mg for each active component.
Q3: Are there overseas equivalents of this patent?
A: Yes, family members exist in Europe, Japan, and other jurisdictions, with corresponding filings from 1999 to 2005.
Q4: What is the legal status of the patent?
A: The patent expired in August 2021, opening the market to generics.
Q5: How has the patent landscape evolved?
A: It includes multiple continuation filings, narrow claims, and ongoing litigation to defend or challenge scope.
References
[1] U.S. Patent Office. (2001). US 6,277,405 B1.
[2] McElroy, B. et al. (2014). "Analysis of Patent Term and Expiration Strategies." Patent Journal.
[3] Johnson, P., & Lee, S. (2019). "Legal Challenges in Patent Litigation." Intellectual Property Law Review.
[4] World Intellectual Property Organization. (2022). Patent Landscape Reports.
